First AD

Second AD

Thoracic oncologists evaluate emerging data presented at the ASCO 2020 virtual meeting on agents for the treatment of 

Data from the following clinical trials are discussed:

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with 

exon 20 insertions. (Piotrowska Z et al. 2020 ASCO annual meeting. Abstract 9513.)

Poziotinib shows activity and durability of responses in subgroups of previously treated 

exon 20 NSCLC patients. (Le X at al. 2020 ASCO annual meeting. Abstract 9514.)

Amivantamab (JNJ-61186372), an anti–EGFR-MET bispecific antibody, in patients with 

exon 20 insertion-mutated non–small cell lung cancer. (Park K et al. 2020 ASCO annual meeting. Abstract 9512.)

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

EGFR Exon 20 Mutations in NSCLC

Data from the following clinical trials are discussed:

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. (Piotrowska Z et al. 2020 ASCO annual meeting. Abstract 9513.)

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. (Le X at al. 2020 ASCO annual meeting. Abstract 9514.)

Amivantamab (JNJ-61186372), an anti–EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion-mutated non–small cell lung cancer. (Park K et al. 2020 ASCO annual meeting. Abstract 9512.)